Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 03 Apr 2018 Planned End Date changed from 1 Oct 2020 to 1 Nov 2025.
- 03 Apr 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Nov 2020.
- 10 Nov 2015 New trial record